Epidemiological Description of Health Determinants in Italian Anticoagulated Population

Anticoagulants Clinical Trial

— EDIA  

Official title:

Epidemiological Description of Health Determinants in Italian Anticoagulated Population (EDIA): a Cross-sectional and Multicenter Study Design

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05710562
• Other study ID #: 88/INT/2018
• Status: Recruiting
• Start date: February 5, 2019
• Est. completion date: December 31, 2024

Study information

• Verified date: February 2023
• Source: IRCCS Policlinico S. Donato
• Contact: Arianna AM Magon, PhD
• Phone: +39 0252774940
• Email: arianna.magon[@]grupposandonato.it
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The primary aim of this study is to describe and develop a cross-sectional profile of the level of the main health determinants in the Italian anticoagulated population (disease knowledge; self-efficacy; health literacy; quality of life). Indeed, evaluate how socio-demographic and clinical data may affect the same relations. Furthermore, the secondary aim is to describe relationships between health determinants and anticoagulation control (i.e., Time in Therapeutic Range, TTR%, or absence of clinical complications). To evaluate the impact of socio-demographic and clinical data on the relationship between health determinants and anticoagulation control.

Description:

Oral Anticoagulation Therapy (OAC) is the leading therapeutic choice in treating and preventing diverse cardiovascular diseases, such as non-valvular atrial fibrillation and venous thromboembolism. Therefore, several empirical studies inquired on which are the main health determinants involved in promoting therapeutic adherence and well-being in the population affected by chronic disease. However, few studies tested the effect of the health determinants on anticoagulation control in reducing thromboembolic and hemorrhagic complications.

The majority of these studies focused their attention on the knowledge level assessment, which results to be a positive predictor of adequate treatment adherence. Moreover, the same knowledge is predicted by adequate Health Literacy (HL). Nevertheless, the disease patients' knowledge results to be generally very low, as well as the levels of HL and treatment adherence behaviors. Furthermore, patients are often unaware of how the drug works, their possible interactions, and side effects, and they often perceive a low quality of life. Indeed, it is not easy to summarize the available evidence because studies' results are often not comparable, considering the diverse measurements to assess the same theoretical constructs. Those measurements, in some cases, also present weaknesses in psychometric evidence of validity and reliability. Finally, the effects of some constructs, how self-efficacy and self-care, are still unexplored.

In light of these considerations, currently, nobody of these health determinants has been studied in the Italian anticoagulated population through the best available tools. The results coming from this study may lead to a more depth awareness of which are the main needs of those patients to reach good anticoagulation control, allowing healthcare providers to better address the personalized educational interventions aimed to improve the skills of patients in clinical decision-making on their own health condition.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1495
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Age greater or equal to18 years

• Outpatients

• Patients treated with oral anticoagulation therapy for at least three mounts

Exclusion Criteria:

• Patients treated with oral anticoagulant therapy for a brief period (i.e., treatment < 6 months)

• Patients with severe comorbidity (i.e., Charlson Comorbidity Index, ICC > 4)

• Patients who have suspended oral anticoagulation therapy for surgery in the last three months

• Cognitive impairment (assessed using a six-item screener)

Related Conditions & MeSH terms

• Anticoagulants

Intervention

Other:
• Name not applicable
In this study, we do not provide any type of intervention but only require the fulfillment of self-report tools by patients during their routine outpatients visit.

Locations

Country	Name	City	State
Italy	IRCCS Policlinico San Donato	San Donato Milanese	MI

Sponsors (1)

Lead Sponsor	Collaborator
IRCCS Policlinico S. Donato

Country where clinical trial is conducted

Italy, 

References & Publications (1)

Magon A, Arrigoni C, Moia M, Mancini M, Dellafiore F, Manara DF, Caruso R. Determinants of health-related quality of life: a cross-sectional investigation in physician-managed anticoagulated patients using vitamin K antagonists. Health Qual Life Outcomes. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Anticoagulation knowledge	This outcome will be measured through the Anticoagulation Knowledge tool: a self-report tool to assess the general anticoagulation knowledge for any OAC treatment. Higher level scores indicate better knowledge.	Day 1 (at the time of data collection)
Primary	Health literacy	This outcome will be measured through the Health Literacy Questionnaire: a self-report and multi-dimensional tool assess HL at functional, communicative/interactive, and critical levels. These dimensions provide an assessment of how the person understand access to and use of health information and health services. The final score is computed for each sub-scale and higher levels indicate better health literacy levels.	Day 1 (at the time of data collection)
Primary	Quality of life (mental and physical wellbeing)	This outcome will be measured through the Short form survey: a self-report tool to assess physical and mental health. The score is computed for each domain (physical and mental health) and higher levels indicate better quality of life perception.	Day 1 (at the time of data collection)
Primary	General self-efficay	This outcome will be measured through the General Self-Efficacy Scale: a self-report tool to assess the level of a personals confidence to do something. The general score ranged between 0 to 100 and higher levels indicate better general self-efficacy.	Day 1 (at the time of data collection)
Primary	Beliefs	This outcome will be measured through the Beliefs about Medicines Questionnaire: a self-report tool to assess the patient's beliefs and attitudes on the necessity and concerns of drug prescription. The final score is computed for each domain.	Day 1 (at the time of data collection)
Secondary	Anticoagulation control	Time in therapeutic range (TTR%) in the last three months (for patients taking VKA therapy).	Day 1 (at the time of data collection)

External Links

•   Related Info